Log In
BCIQ
Print this Print this
 

BPS-804

  Manage Alerts
Collapse Summary General Information
Company Mereo BioPharma Group Ltd.
DescriptionHuman mAb inhibiting sclerostin
Molecular Target Sclerostin
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationOsteoporosis
Indication DetailsTreat osteogenesis imperfecta (OI)
Regulatory Designation U.S. - Orphan Drug (Treat osteogenesis imperfecta (OI));
EU - Orphan Drug (Treat osteogenesis imperfecta (OI))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/29/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today